Non-Culprit MACE Rate in LRP: The Influence of Optimal Medical Therapy Using DAPT and Statins. | Non-culprit MACE-rate in LRP: The influence of optimal medical therapy using DAPT and statins.
Non-Culprit MACE Rate in LRP: The Influence of Optimal Medical Therapy Using DAPT and Statins. Non-culprit MACE-rate in LRP: The influence of optimal medical therapy using DAPT and statins.
- 2022
BACKGROUND/PURPOSE: The Lipid Rich Plaque (LRP) study demonstrated the association between coronary plaque lipid content and outcomes. In this LRP substudy, we assessed the impact of optimal medical therapy (OMT) on the occurrence of non-culprit major adverse cardiac events (NC-MACE). Advanced intracoronary imaging modalities are able to identify patients with vulnerable coronary lesion morphology associated with future events. CONCLUSIONS: In the current LRP analysis, we could not identify a beneficial effect of OMT in the reduction of NC-MACE rate, even in patients with high-risk plaques during 24-month follow-up. Copyright (c) 2021. Published by Elsevier Inc. METHODS/MATERIALS: A total of 1270 patients who underwent cardiac catheterization for suspected coronary artery disease (CAD) with evaluable maxLCBI4mm in non-culprit vessels and known medical therapy after discharge were followed for 2 years. OMT was defined as the use of a statin and dual antiplatelet therapy (DAPT). RESULTS: Among the 1270 patients included in this substudy, 1110 (87.7%) had PCI for an index event, and 1014 (80%) patients received OMT. Estimated cumulative incidence functions of NC-MACE did not differ significantly between patients treated with or without OMT (log-rank p-value = 0.876). In patients labeled high risk (maxLCBI4mm > 400), cumulative incidence function also did not differ between patients treated with vs without OMT (log-rank p-value = 0.19).
English
1878-0938
*Coronary Artery Disease
*Hydroxymethylglutaryl-CoA Reductase Inhibitors
*Percutaneous Coronary Intervention
*Plaque, Atherosclerotic
Coronary Artery Disease/co [Complications]
Coronary Artery Disease/dg [Diagnostic Imaging]
Coronary Artery Disease/th [Therapy]
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors/ae [Adverse Effects]
Lipids
Percutaneous Coronary Intervention/ae [Adverse Effects]
Percutaneous Coronary Intervention/mt [Methods]
Plaque, Atherosclerotic/pa [Pathology]
Platelet Aggregation Inhibitors/ae [Adverse Effects]
Treatment Outcome
MedStar Heart & Vascular Institute
MedStar Heart & Vascular Institute
Journal Article
BACKGROUND/PURPOSE: The Lipid Rich Plaque (LRP) study demonstrated the association between coronary plaque lipid content and outcomes. In this LRP substudy, we assessed the impact of optimal medical therapy (OMT) on the occurrence of non-culprit major adverse cardiac events (NC-MACE). Advanced intracoronary imaging modalities are able to identify patients with vulnerable coronary lesion morphology associated with future events. CONCLUSIONS: In the current LRP analysis, we could not identify a beneficial effect of OMT in the reduction of NC-MACE rate, even in patients with high-risk plaques during 24-month follow-up. Copyright (c) 2021. Published by Elsevier Inc. METHODS/MATERIALS: A total of 1270 patients who underwent cardiac catheterization for suspected coronary artery disease (CAD) with evaluable maxLCBI4mm in non-culprit vessels and known medical therapy after discharge were followed for 2 years. OMT was defined as the use of a statin and dual antiplatelet therapy (DAPT). RESULTS: Among the 1270 patients included in this substudy, 1110 (87.7%) had PCI for an index event, and 1014 (80%) patients received OMT. Estimated cumulative incidence functions of NC-MACE did not differ significantly between patients treated with or without OMT (log-rank p-value = 0.876). In patients labeled high risk (maxLCBI4mm > 400), cumulative incidence function also did not differ between patients treated with vs without OMT (log-rank p-value = 0.19).
English
1878-0938
*Coronary Artery Disease
*Hydroxymethylglutaryl-CoA Reductase Inhibitors
*Percutaneous Coronary Intervention
*Plaque, Atherosclerotic
Coronary Artery Disease/co [Complications]
Coronary Artery Disease/dg [Diagnostic Imaging]
Coronary Artery Disease/th [Therapy]
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors/ae [Adverse Effects]
Lipids
Percutaneous Coronary Intervention/ae [Adverse Effects]
Percutaneous Coronary Intervention/mt [Methods]
Plaque, Atherosclerotic/pa [Pathology]
Platelet Aggregation Inhibitors/ae [Adverse Effects]
Treatment Outcome
MedStar Heart & Vascular Institute
MedStar Heart & Vascular Institute
Journal Article